CG Oncology, Inc. Common stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGON research report →
Companycgoncology.com
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
- CEO
- Arthur Kuan
- IPO
- 2024
- Employees
- 113
- HQ
- Irvine, DE, US
Price Chart
Valuation
- Market Cap
- $5.71B
- P/E
- -29.31
- P/S
- 1126.40
- P/B
- 5.01
- EV/EBITDA
- -28.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -46.97%
- Op Margin
- -4238.99%
- Net Margin
- -3682.61%
- ROE
- -23.33%
- ROIC
- -19.52%
Growth & Income
- Revenue
- $4.04M · 254.70%
- Net Income
- $-160,995,000 · -82.87%
- EPS
- $-2.08 · -47.52%
- Op Income
- $-190,774,000
- FCF YoY
- -67.81%
Performance & Tape
- 52W High
- $75.50
- 52W Low
- $23.65
- 50D MA
- $67.24
- 200D MA
- $48.38
- Beta
- 0.42
- Avg Volume
- 1.23M
Get TickerSpark's AI analysis on CGON
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Mulay James | other | 15,600 |
| Apr 17, 26 | Mulay James | sell | 15,600 |
| Apr 17, 26 | Mulay James | other | 15,600 |
| Apr 15, 26 | Bellete Ambaw | other | 107,508 |
| Apr 15, 26 | Kasturi Vijay | other | 79,216 |
| Apr 15, 26 | Patterson Joshua F. | other | 45,266 |
| Apr 15, 26 | DETORE JAMES M. | other | 90,574 |
| Apr 15, 26 | Kuan Arthur | other | 271,600 |
| Mar 16, 26 | Mulay James | other | 1,310 |
| Mar 16, 26 | Mulay James | other | 1,310 |
Our CGON Coverage
We haven't published any research on CGON yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CGON Report →